2012 Fourth Quarter - released 06 February 2013
Simon Dingemans, CFO, and Sir Andrew Witty, CEO, discuss our fourth quarter results 2012.
- Core EPS of 112.7p and returns of £6.3bn to shareholders
- 2012 dividend of 74p (+6%)
- Group sales -1%; flat excluding disposals of OTC brands
- Successful R&D delivery: six new drugs filed since start of 2012
2012 Third Quarter - released 31 October 2012
Simon Dingemans, CFO, discusses our Q3 results 2012.
- Core EPS of 26.5p
- Dividend of 18p (+ 6%)
- Further successful R&D delivery: phase III programmes completed for 6 novel medicines in 2012
- Continued strong cash generation and returns to shareholders
2012 Second Quarter - released 25 July 2012
Watch Sir Andrew Witty, CEO, discuss our second quarter results 2012.
- Core EPS of 26.4p
- Dividend of 17p (up 6%)
- Significant late-stage pipeline delivery
2012 First Quarter - released 25 April 2012
Watch Simon Dingemans, CFO, discuss our first quarter results 2012.
- Sales growth of +2% CER
- Further R&D delivery, operational leverage and continued returns to shareholders
- Core EPS 27.3p (+7%), dividend up 6% to 17p
Other key information
Speeches & presentations
Search through our archive of speeches and presentations from conferences and events
Keep up to date with our news and recent announcements
A snapshot of our medicines and vaccines currently in development across three stages: phase I, phase II and phase III
Corporate Executive Team
The Corporate Executive Team manages our activities, and each member is responsible for a specific part of the business